<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05059613</url>
  </required_header>
  <id_info>
    <org_study_id>jcl2021-8</org_study_id>
    <nct_id>NCT05059613</nct_id>
  </id_info>
  <brief_title>Thalidomide With or Without Probiotics in Radioactive Oral Mucositis</brief_title>
  <official_title>Study on Thalidomide With or Without Probiotics in Radioactive Oral Mucositis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangxi Provincial Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangxi Provincial Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study on the application of thalidomide with or without probiotics in radioactive oral&#xD;
      mucositis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiation oral mucositis is an acute mucous membrane reaction in patients undergoing&#xD;
      radiotherapy of the head and neck. It can cause dose limitation and debilitating side&#xD;
      effects. There is no accepted guideline that can significantly reduce its severity. In the&#xD;
      mucosa, T and B cells of the immune system have location-specific phenotypes and functions&#xD;
      that are influenced by the microbiome. These cells play a key role in maintaining immune&#xD;
      homeostasis by inhibiting responses to harmless antigens and enhancing the integrity of&#xD;
      intestinal mucosal barrier function. We designed a clinical study of thalidomide with or&#xD;
      without probiotics in radioactive oral mucositis. The aim of this study was to determine&#xD;
      whether regulation of intestinal flora can effectively reduce the severity of&#xD;
      radiation-induced mucositis in patients undergoing radical radiation therapy. The researchers&#xD;
      also investigated the effect of the intervention on patients' general well-being. The primary&#xD;
      endpoint was the incidence of grade 3 mucositis in the radiotherapy oncology group. In 2021,&#xD;
      an estimated 40 patients were enrolled in the study at Jiangxi Cancer Hospital in China.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 20, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the incidence of Radiation Therapy Oncology Group grade 3 mucositis</measure>
    <time_frame>one month</time_frame>
    <description>Radiation oral mucositis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the variaty of immune index</measure>
    <time_frame>one month</time_frame>
    <description>CD3,CD4,CD8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the variaty of immune index</measure>
    <time_frame>one month</time_frame>
    <description>Hemoglobin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the variaty of immune index</measure>
    <time_frame>one month</time_frame>
    <description>lymphocyte ratio</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Oral Mucositis</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>probiotics group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use thalidomide in combination with probiotics during radiotherapy and chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>thalidomide group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Thalidomide is used only during radiotherapy and chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>healthy control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>probiotics</intervention_name>
    <description>one times a day during the whole treatment</description>
    <arm_group_label>probiotics group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Karnofsky score â‰¥80 ,newly diagnosed NPC without distant metastasis, confirmed by&#xD;
             pathology without any other malignant disease history ,no any other anti-cancer&#xD;
             treatment for NPC previously ,received radiotherapy and chemotherapy at our Cancer&#xD;
             Center&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any immune system disease under high risk to antimicrobial agents such as&#xD;
             Diabetes,infection disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunling Jiang, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangxi Provincial Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunling Jiang, MD PHD</last_name>
    <phone>13979109200</phone>
    <email>jclil2002@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jiangxi Cancer Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330029</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chunling Jiang, MD phd</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 31, 2021</study_first_submitted>
  <study_first_submitted_qc>September 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2021</study_first_posted>
  <last_update_submitted>September 19, 2021</last_update_submitted>
  <last_update_submitted_qc>September 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

